Inhibition of VEGFR-2 reverses type 1 diabetes in nod mice by abrogating insulitis and restoring islet function

S. Armando Villalta, Jiena Lang, Samantha Kubeck, Beniwende Kabre, Gregory L. Szot, Boris Calderon, Clive Wasserfall, Mark A. Atkinson, Rolf A. Brekken, Nick Pullen, Robert H. Arch, Jeffrey A. Bluestone

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The dysregulation of receptor tyrosine kinases (RTKs) in multiple cell types during chronic inflammation is indicative of their pathogenic role in autoimmune diseases. Among the many RTKs, vascular endothelial growth factor receptor (VEGFR) stands out for its multiple effects on immunity, vascularization, and cell migration. Herein, we examined whether VEGFR participated in the pathogenesis of type 1 diabetes (T1D) in nonobese diabetic (NOD) mice. We found that RTK inhibitors (RTKIs) and VEGF or VEGFR-2 antibodies reversed diabetes when administered at the onset of hyperglycemia. Increased VEGF expression promoted islet vascular remodeling in NOD mice, and inhibition of VEGFR activity with RTKIs abrogated the increase in islet vascularity, impairing T-cell migration into the islet and improving glucose control. Metabolic studies confirmed that RTKIs worked by preserving islet function, as treated mice had improved glucose tolerance without affecting insulin sensitivity. Finally, examination of human pancreata from patients with T1D revealed that VEGFR-2 was confined to the islet vascularity, which was increased in inflamed islets. Collectively, this work reveals a previously unappreciated role for VEGFR-2 signaling in the pathogenesis of T1D by controlling T-cell accessibility to the pancreatic islets and highlights a novel application of VEGFR-2 antagonists for the therapeutic treatment of T1D.

Original languageEnglish (US)
Pages (from-to)2870-2878
Number of pages9
JournalDiabetes
Volume62
Issue number8
DOIs
StatePublished - Aug 2013

Fingerprint

Vascular Endothelial Growth Factor Receptor-2
Type 1 Diabetes Mellitus
Receptor Protein-Tyrosine Kinases
Inbred NOD Mouse
Vascular Endothelial Growth Factor Receptor
Vascular Endothelial Growth Factor A
Cell Movement
T-Lymphocytes
Glucose
Islets of Langerhans
Hyperglycemia
Autoimmune Diseases
Insulin Resistance
Pancreas
Immunity
Inflammation
Antibodies
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Villalta, S. A., Lang, J., Kubeck, S., Kabre, B., Szot, G. L., Calderon, B., ... Bluestone, J. A. (2013). Inhibition of VEGFR-2 reverses type 1 diabetes in nod mice by abrogating insulitis and restoring islet function. Diabetes, 62(8), 2870-2878. https://doi.org/10.2337/db12-1619

Inhibition of VEGFR-2 reverses type 1 diabetes in nod mice by abrogating insulitis and restoring islet function. / Villalta, S. Armando; Lang, Jiena; Kubeck, Samantha; Kabre, Beniwende; Szot, Gregory L.; Calderon, Boris; Wasserfall, Clive; Atkinson, Mark A.; Brekken, Rolf A.; Pullen, Nick; Arch, Robert H.; Bluestone, Jeffrey A.

In: Diabetes, Vol. 62, No. 8, 08.2013, p. 2870-2878.

Research output: Contribution to journalArticle

Villalta, SA, Lang, J, Kubeck, S, Kabre, B, Szot, GL, Calderon, B, Wasserfall, C, Atkinson, MA, Brekken, RA, Pullen, N, Arch, RH & Bluestone, JA 2013, 'Inhibition of VEGFR-2 reverses type 1 diabetes in nod mice by abrogating insulitis and restoring islet function', Diabetes, vol. 62, no. 8, pp. 2870-2878. https://doi.org/10.2337/db12-1619
Villalta, S. Armando ; Lang, Jiena ; Kubeck, Samantha ; Kabre, Beniwende ; Szot, Gregory L. ; Calderon, Boris ; Wasserfall, Clive ; Atkinson, Mark A. ; Brekken, Rolf A. ; Pullen, Nick ; Arch, Robert H. ; Bluestone, Jeffrey A. / Inhibition of VEGFR-2 reverses type 1 diabetes in nod mice by abrogating insulitis and restoring islet function. In: Diabetes. 2013 ; Vol. 62, No. 8. pp. 2870-2878.
@article{bfa734ddf53646cf9a090d798f9c3ba5,
title = "Inhibition of VEGFR-2 reverses type 1 diabetes in nod mice by abrogating insulitis and restoring islet function",
abstract = "The dysregulation of receptor tyrosine kinases (RTKs) in multiple cell types during chronic inflammation is indicative of their pathogenic role in autoimmune diseases. Among the many RTKs, vascular endothelial growth factor receptor (VEGFR) stands out for its multiple effects on immunity, vascularization, and cell migration. Herein, we examined whether VEGFR participated in the pathogenesis of type 1 diabetes (T1D) in nonobese diabetic (NOD) mice. We found that RTK inhibitors (RTKIs) and VEGF or VEGFR-2 antibodies reversed diabetes when administered at the onset of hyperglycemia. Increased VEGF expression promoted islet vascular remodeling in NOD mice, and inhibition of VEGFR activity with RTKIs abrogated the increase in islet vascularity, impairing T-cell migration into the islet and improving glucose control. Metabolic studies confirmed that RTKIs worked by preserving islet function, as treated mice had improved glucose tolerance without affecting insulin sensitivity. Finally, examination of human pancreata from patients with T1D revealed that VEGFR-2 was confined to the islet vascularity, which was increased in inflamed islets. Collectively, this work reveals a previously unappreciated role for VEGFR-2 signaling in the pathogenesis of T1D by controlling T-cell accessibility to the pancreatic islets and highlights a novel application of VEGFR-2 antagonists for the therapeutic treatment of T1D.",
author = "Villalta, {S. Armando} and Jiena Lang and Samantha Kubeck and Beniwende Kabre and Szot, {Gregory L.} and Boris Calderon and Clive Wasserfall and Atkinson, {Mark A.} and Brekken, {Rolf A.} and Nick Pullen and Arch, {Robert H.} and Bluestone, {Jeffrey A.}",
year = "2013",
month = "8",
doi = "10.2337/db12-1619",
language = "English (US)",
volume = "62",
pages = "2870--2878",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "8",

}

TY - JOUR

T1 - Inhibition of VEGFR-2 reverses type 1 diabetes in nod mice by abrogating insulitis and restoring islet function

AU - Villalta, S. Armando

AU - Lang, Jiena

AU - Kubeck, Samantha

AU - Kabre, Beniwende

AU - Szot, Gregory L.

AU - Calderon, Boris

AU - Wasserfall, Clive

AU - Atkinson, Mark A.

AU - Brekken, Rolf A.

AU - Pullen, Nick

AU - Arch, Robert H.

AU - Bluestone, Jeffrey A.

PY - 2013/8

Y1 - 2013/8

N2 - The dysregulation of receptor tyrosine kinases (RTKs) in multiple cell types during chronic inflammation is indicative of their pathogenic role in autoimmune diseases. Among the many RTKs, vascular endothelial growth factor receptor (VEGFR) stands out for its multiple effects on immunity, vascularization, and cell migration. Herein, we examined whether VEGFR participated in the pathogenesis of type 1 diabetes (T1D) in nonobese diabetic (NOD) mice. We found that RTK inhibitors (RTKIs) and VEGF or VEGFR-2 antibodies reversed diabetes when administered at the onset of hyperglycemia. Increased VEGF expression promoted islet vascular remodeling in NOD mice, and inhibition of VEGFR activity with RTKIs abrogated the increase in islet vascularity, impairing T-cell migration into the islet and improving glucose control. Metabolic studies confirmed that RTKIs worked by preserving islet function, as treated mice had improved glucose tolerance without affecting insulin sensitivity. Finally, examination of human pancreata from patients with T1D revealed that VEGFR-2 was confined to the islet vascularity, which was increased in inflamed islets. Collectively, this work reveals a previously unappreciated role for VEGFR-2 signaling in the pathogenesis of T1D by controlling T-cell accessibility to the pancreatic islets and highlights a novel application of VEGFR-2 antagonists for the therapeutic treatment of T1D.

AB - The dysregulation of receptor tyrosine kinases (RTKs) in multiple cell types during chronic inflammation is indicative of their pathogenic role in autoimmune diseases. Among the many RTKs, vascular endothelial growth factor receptor (VEGFR) stands out for its multiple effects on immunity, vascularization, and cell migration. Herein, we examined whether VEGFR participated in the pathogenesis of type 1 diabetes (T1D) in nonobese diabetic (NOD) mice. We found that RTK inhibitors (RTKIs) and VEGF or VEGFR-2 antibodies reversed diabetes when administered at the onset of hyperglycemia. Increased VEGF expression promoted islet vascular remodeling in NOD mice, and inhibition of VEGFR activity with RTKIs abrogated the increase in islet vascularity, impairing T-cell migration into the islet and improving glucose control. Metabolic studies confirmed that RTKIs worked by preserving islet function, as treated mice had improved glucose tolerance without affecting insulin sensitivity. Finally, examination of human pancreata from patients with T1D revealed that VEGFR-2 was confined to the islet vascularity, which was increased in inflamed islets. Collectively, this work reveals a previously unappreciated role for VEGFR-2 signaling in the pathogenesis of T1D by controlling T-cell accessibility to the pancreatic islets and highlights a novel application of VEGFR-2 antagonists for the therapeutic treatment of T1D.

UR - http://www.scopus.com/inward/record.url?scp=84891716474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891716474&partnerID=8YFLogxK

U2 - 10.2337/db12-1619

DO - 10.2337/db12-1619

M3 - Article

C2 - 23835340

AN - SCOPUS:84891716474

VL - 62

SP - 2870

EP - 2878

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 8

ER -